Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Plasma cell 1

Conditions

Multiple Myeloma 26Burkitt Lymphoma 15Precursor Cell Lymphoblastic Leukemia-Lymphoma 9Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 8Precursor B-Cell Lymphoblastic Leukemia-Lymphoma 4Immunoglobulin Light-chain Amyloidosis 4Smoldering Multiple Myeloma 3Neoplasm Metastasis 3Leukemia, Biphenotypic, Acute 3Down Syndrome 3Carcinoma, Non-Small-Cell Lung 3Neoplasms 2Lymphoma, Mantle-Cell 2Lymphoma, Large B-Cell, Diffuse 2Lymphoma 2Lung Neoplasms 2Hodgkin Disease 2Breast Neoplasms 2Brain Neoplasms 2Blastic Plasmacytoid Dendritic Cell Neoplasm 2Recurrence 1Plasmacytoma 1Meningioma 1Mastocytosis, Systemic 1Lymphoma, B-Cell, Marginal Zone 1Leukemia, Plasma Cell 1Leukemia, Myelomonocytic, Chronic 1Leukemia, Myeloid, Acute 1Leukemia, Myeloid, Accelerated Phase 1Leukemia, Myelogenous, Chronic, BCR-ABL Positive 1

Interventions

Dexamethasone 4Cyclophosphamide 4Bortezomib 3daratumumab 2belantamab mafodotin 2venetoclax 1pegfilgrastim 1ixazomib 1dexamethasone acetate 1dexamethasone 21-phosphate 1auricularum 1Lenalidomide 1Calcium Dobesilate 1Antineoplastic Protocols 14-(N-methylamino)-4'-(2-(2-(2-fluoroethoxy)ethoxy)ethoxy)stilbene 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Amyloidosis × auricularum × 1 year × Clear all
NCT01864018 2025-07-24

Ixazomib With Cyclophosphamide and Dexamethasone in Patients With Previously Untreated Symptomatic Multiple Myeloma or Light Chain Amyloidosis

Mayo Clinic

Phase 1/2 Completed
87 enrolled 13 charts
Plasma cell

Amyloidosis, Multiple Myeloma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡